CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 2B Single-site, Open-label, Nonrandomized Study Evaluating the Efficacy of Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02306850
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:15.369791+00:00
Published At: 2019-06-20T00:00:00+00:00
Record Updated At: 2019-06-20
Results Posted At: 2019-06-20
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Unresectable Malignant Neoplasm", "Melanoma", "Metastatic Melanoma", "Stage IV Melanoma", "Stage III Melanoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2019-06-20"
protocolSection.identificationModule.nctId: "NCT02306850"
protocolSection.identificationModule.officialTitle: "Phase 2B Single-site, Open-label, Nonrandomized Study Evaluating the Efficacy of Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2019-06-20"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.